BioCentury | Sep 1, 2017
Company News

Janssen gains MDD compound CERC-501 from Cerecor

...to develop and commercialize CERC-501 (see BioCentury March 9, 2015 ). Cerecor's remaining pipeline includes CERC-301...
BioCentury | Feb 10, 2017
Clinical News

CERC-301: Ph II Clin301-203 data

...trial in 115 MDD patients showing that adjunctive treatment with 12 and 20 mg oral CERC-301...
...1 were re-randomized to CERC-301 or placebo in Period 2. Cerecor also said that high-dose CERC-301...
...Cerecor Inc. (NASDAQ:CERC), Baltimore, Md. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Product: CERC-301 , MK-0657...
BioCentury | Sep 26, 2016
Clinical News

CERC-301: Completed Phase II enrollment

...in the double-blind, placebo-controlled, U.S. Phase II Clin301-203 trial evaluating 12 and 20 mg oral CERC-301...
...inhibitor (SSRI) or a serotonin norepinephrine reuptake inhibitor (SNRI). Cerecor has exclusive, worldwide rights to CERC-301...
...Cerecor Inc. (NASDAQ:CERC), Baltimore, Md. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Product: CERC-301 , MK-0657...
BioCentury | Oct 16, 2015
Financial News

Cerecor raises $26M in IPO

...see BioCentury, Oct. 12) . Cerecor expects data in 2H16 from Phase II trials of CERC-301...
...major depressive disorder (MDD) and CERC-501 for adjunctive treatment of MDD and substance use disorders. CERC-301...
BioCentury | Sep 7, 2015
Clinical News

CERC-301: Phase II started

...the double-blind, placebo-controlled, U.S. Phase II Clin301-202 trial to evaluate 12 and 20 mg oral CERC-301...
...reuptake inhibitor (SSRI) or serotonin norepinephrine reuptake inhibitor (SNRI). Cerecor has exclusive, worldwide rights to CERC-301...
...Cerecor Inc. , Baltimore, Md. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Product: CERC-301 , MK-0657...
BioCentury | Mar 30, 2015
Clinical News

CERC-301: Phase II data

...HDRS-17 score from baseline to day 7 vs. placebo. CERC-301 was well tolerated. Patients received CERC-301...
...dosing regimen of CERC-301. Cerecor has exclusive, worldwide rights from Merck to develop and commercialize CERC-301...
...Inc. , Baltimore, Md. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: CERC-301 , MK-0657...
BioCentury | Jul 22, 2014
Top Story

Cerecor raises $15 million in B round

...New investors New Enterprise Associates; Apple Tree Partners; and MPM Capital led the tranche. Cerecor's CERC-301...
BioCentury | Dec 9, 2013
Clinical News

CERC-301 regulatory update

...FDA granted Fast Track designation to CERC-301 to treat major depressive disorder (MDD). Cerecor expects data...
...MDD by year end. Cerecor acquired exclusive, worldwide rights from Merck to develop and commercialize CERC-301...
...Inc. , Baltimore, Md. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: CERC-301 , MK-0657...
BioCentury | Nov 18, 2013
Clinical News

MK-0657: Phase II started

...Cerecor began a double-blind Phase II trial to evaluate 8 or 12 mg CERC-301 in about...
...treatment with selective serotonin reuptake inhibitors (SSRI) or serotonin-norepinephrine reuptake inhibitors (SNRI). Patients will receive CERC-301...
...Inc. , Baltimore, Md. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: MK-0657 , CERC-301...
BioCentury | Oct 24, 2013
Strategy

Synaptic synopsis

...glutamate receptor subtype 5 (mGluR5; GRM5) Roche RG7090 Phase II Depression GRIN2B (NR2B) Cerecor Inc. CERC-301...
Items per page:
1 - 10 of 12